Should You Buy Or Sell Monsanto Company (MON) Following Mixed Results?

Page 2 of 2

When looking at the hedgies followed by Insider Monkey, Glenview Capital, managed by Larry Robbins, holds the number one position in Monsanto Company (NYSE:MON), with a $1.09 billion stake that contained 9.69 million shares by the end of the first quarter. This stake comprised 5% of Glenview Capital’s 13F portfolio. D E Shaw, managed by David E. Shaw, came in second as it held a $365.2 million position. Some other peers that hold long positions include Alan Fournier’s Pennant Capital Management, Jeffrey Tannenbaum’s Fir Tree and Jonathon Jacobson’s Highfields Capital Management.

Judging by the fact that Monsanto Company (NYSE:MON) has witnessed some bearish sentiment from hedge fund managers, it’s easy to see that there is a number of money managers that elected to cut their positions entirely heading into the second quarter. Intriguingly, Keith Meister‘s Corvex Capital sold out the largest investment among all the hedge funds tracked by Insider Monkey after dumping about 2.42 million shares of Monsanto Company. Benjamin A. Smith’s fund, Laurion Capital Management, also closed its position, which contained 1.0 million shares.

Given the drop in hedge fund interest and unchanged insider sentiment coupled with the mixed result for its third quarter for the fiscal year 2015, Monsanto Company (NYSE:MON) does not seem to be a good buy for now.

Disclosure: None

Page 2 of 2